Graig Suvannavejh
Stock Analyst at Mizuho
(2.31)
# 2,579
Out of 4,886 analysts
154
Total ratings
44.44%
Success rate
-3.01%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Graig Suvannavejh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ADVM Adverum Biotechnologies | Maintains: Outperform | $16 → $12 | $2.40 | +400.00% | 5 | Jun 26, 2025 | |
| ADAP Adaptimmune Therapeutics | Downgrades: Neutral | $1.5 → $0.5 | $0.25 | +97.63% | 3 | Jun 26, 2025 | |
| IMRX Immuneering | Maintains: Outperform | $8 → $10 | $4.00 | +150.00% | 2 | Jun 18, 2025 | |
| INSM Insmed | Maintains: Outperform | $96 → $110 | $96.14 | +14.42% | 10 | Jun 11, 2025 | |
| CRVS Corvus Pharmaceuticals | Maintains: Outperform | $12 → $11 | $3.96 | +177.78% | 2 | May 20, 2025 | |
| EYPT EyePoint Pharmaceuticals | Maintains: Outperform | $30 → $26 | $9.93 | +161.83% | 5 | May 16, 2025 | |
| HRMY Harmony Biosciences Holdings | Maintains: Outperform | $44 → $48 | $32.75 | +46.56% | 18 | May 15, 2025 | |
| APLS Apellis Pharmaceuticals | Maintains: Neutral | $30 → $20 | $17.89 | +11.79% | 7 | May 14, 2025 | |
| AMLX Amylyx Pharmaceuticals | Maintains: Outperform | $7 → $8 | $6.98 | +14.61% | 7 | May 14, 2025 | |
| IMCR Immunocore Holdings | Maintains: Neutral | $38 → $33 | $33.28 | -0.84% | 8 | Apr 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $212 → $216 | $108.41 | +99.24% | 21 | Mar 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $7 → $7.6 | $2.36 | +222.03% | 1 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $74 | $7.54 | +881.43% | 1 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $5 → $0.5 | $0.37 | +35.14% | 3 | Sep 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $44 → $49 | $55.79 | -12.17% | 6 | Jul 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $50 | $21.45 | +133.10% | 1 | Jul 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $20 | $0.90 | +2,118.03% | 1 | Jul 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $14 → $16 | $5.67 | +182.19% | 3 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $17 → $10 | $4.53 | +120.75% | 5 | Nov 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $9 | $1.53 | +488.24% | 4 | Nov 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $64 | $2.01 | +3,084.08% | 8 | Aug 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $17 → $1 | $3.58 | -72.07% | 5 | Jun 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $15 | $8.02 | +87.03% | 1 | Mar 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $31 → $35 | $65.14 | -46.27% | 5 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $9 → $8 | $3.90 | +105.13% | 6 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $71 → $57 | $34.25 | +66.42% | 2 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $8 → $5 | $35.61 | -85.96% | 4 | Apr 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $34 | $5.84 | +482.69% | 1 | Jun 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $28 | $3.63 | +671.35% | 1 | Apr 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $31 | $13.03 | +137.91% | 1 | Apr 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sell | $19 | $2.40 | +691.67% | 1 | Mar 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $4.75 | $1.75 | +171.43% | 1 | Nov 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $36 | $13.76 | +161.63% | 2 | Nov 9, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | n/a | $28.81 | - | 1 | Oct 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $37 | $0.88 | +4,125.67% | 1 | Oct 20, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $128 | $109.13 | +17.29% | 1 | Sep 14, 2020 |
Adverum Biotechnologies
Jun 26, 2025
Maintains: Outperform
Price Target: $16 → $12
Current: $2.40
Upside: +400.00%
Adaptimmune Therapeutics
Jun 26, 2025
Downgrades: Neutral
Price Target: $1.5 → $0.5
Current: $0.25
Upside: +97.63%
Immuneering
Jun 18, 2025
Maintains: Outperform
Price Target: $8 → $10
Current: $4.00
Upside: +150.00%
Insmed
Jun 11, 2025
Maintains: Outperform
Price Target: $96 → $110
Current: $96.14
Upside: +14.42%
Corvus Pharmaceuticals
May 20, 2025
Maintains: Outperform
Price Target: $12 → $11
Current: $3.96
Upside: +177.78%
EyePoint Pharmaceuticals
May 16, 2025
Maintains: Outperform
Price Target: $30 → $26
Current: $9.93
Upside: +161.83%
Harmony Biosciences Holdings
May 15, 2025
Maintains: Outperform
Price Target: $44 → $48
Current: $32.75
Upside: +46.56%
Apellis Pharmaceuticals
May 14, 2025
Maintains: Neutral
Price Target: $30 → $20
Current: $17.89
Upside: +11.79%
Amylyx Pharmaceuticals
May 14, 2025
Maintains: Outperform
Price Target: $7 → $8
Current: $6.98
Upside: +14.61%
Immunocore Holdings
Apr 7, 2025
Maintains: Neutral
Price Target: $38 → $33
Current: $33.28
Upside: -0.84%
Mar 27, 2025
Maintains: Outperform
Price Target: $212 → $216
Current: $108.41
Upside: +99.24%
Nov 18, 2024
Upgrades: Buy
Price Target: $7 → $7.6
Current: $2.36
Upside: +222.03%
Sep 20, 2024
Reiterates: Outperform
Price Target: $74
Current: $7.54
Upside: +881.43%
Sep 19, 2024
Downgrades: Neutral
Price Target: $5 → $0.5
Current: $0.37
Upside: +35.14%
Jul 22, 2024
Maintains: Neutral
Price Target: $44 → $49
Current: $55.79
Upside: -12.17%
Jul 8, 2024
Initiates: Outperform
Price Target: $50
Current: $21.45
Upside: +133.10%
Jul 8, 2024
Initiates: Outperform
Price Target: $20
Current: $0.90
Upside: +2,118.03%
May 16, 2024
Maintains: Buy
Price Target: $14 → $16
Current: $5.67
Upside: +182.19%
Nov 27, 2023
Maintains: Buy
Price Target: $17 → $10
Current: $4.53
Upside: +120.75%
Nov 17, 2023
Maintains: Buy
Price Target: $10 → $9
Current: $1.53
Upside: +488.24%
Aug 23, 2023
Reiterates: Neutral
Price Target: $64
Current: $2.01
Upside: +3,084.08%
Jun 5, 2023
Downgrades: Neutral
Price Target: $17 → $1
Current: $3.58
Upside: -72.07%
Mar 31, 2023
Initiates: Buy
Price Target: $15
Current: $8.02
Upside: +87.03%
Nov 10, 2022
Maintains: Buy
Price Target: $31 → $35
Current: $65.14
Upside: -46.27%
Nov 10, 2022
Maintains: Neutral
Price Target: $9 → $8
Current: $3.90
Upside: +105.13%
May 24, 2022
Maintains: Buy
Price Target: $71 → $57
Current: $34.25
Upside: +66.42%
Apr 19, 2022
Maintains: Sell
Price Target: $8 → $5
Current: $35.61
Upside: -85.96%
Jun 1, 2021
Initiates: Buy
Price Target: $34
Current: $5.84
Upside: +482.69%
Apr 20, 2021
Initiates: Neutral
Price Target: $28
Current: $3.63
Upside: +671.35%
Apr 19, 2021
Initiates: Neutral
Price Target: $31
Current: $13.03
Upside: +137.91%
Mar 2, 2021
Initiates: Sell
Price Target: $19
Current: $2.40
Upside: +691.67%
Nov 24, 2020
Initiates: Neutral
Price Target: $4.75
Current: $1.75
Upside: +171.43%
Nov 9, 2020
Upgrades: Buy
Price Target: $36
Current: $13.76
Upside: +161.63%
Oct 21, 2020
Downgrades: Sell
Price Target: n/a
Current: $28.81
Upside: -
Oct 20, 2020
Initiates: Neutral
Price Target: $37
Current: $0.88
Upside: +4,125.67%
Sep 14, 2020
Downgrades: Sell
Price Target: $128
Current: $109.13
Upside: +17.29%